As Clara's treatment begins, the role of Biozyme-X and its kinetic parameters become crucial. In Clara's case, the enzyme was hyperactive due to some internal mutations of its amino acids, leading to an overproduction of a certain metabolite causing her symptoms. Clara's doctor prescribes the drug Zelphorin, a competitive inhibitor of Biozyme-X. Zelphorin had shown promising results in clinical trials by targeting Biozyme-X in patients with this autoimmune disorder. In the presence of Zelphorin, the drug competes with the natural substrate of Biozyme-X for the enzyme's active site, reducing the hyperactivity of the enzyme.
Over the next few weeks after taking Zelphorin, Clara began to notice a decrease in her joint pain and fatigue. However, she experienced some unexpected side effects, including digestive issues and mild tremors. Concerned, she returned to Dr. Rodriguez. Upon further analysis, Dr. Rodriguez discovered that Clara was also taking another medication for her migraines, named Migranil. Migranil, as it turned out, was a noncompetitive inhibitor of Biozyme-X. Unlike Zelphorin, Migranil binds to an allosteric site on Biozyme-X, changing the enzyme's shape and making it less effective. the introduction of Migranil further complicates Clara's medical landscape as it messes with the effect of Zelphorin, making it even less active. Upon talking with Dr. Rodriguez, Clara found that the competitive inhibitor and non-competitive inhibitors work differently with the enzyme and it is not possible to reverse the effects of Migranil easily unlike that of Zelphorin, which can simply be accomplished by the addition of more substrate to the enzyme. This situation presents a unique opportunity to explore the world of enzyme inhibition and its diverse types, each with a distinct impact on Biozyme-X and other enzymes. Each of these agents offers further insight into the diverse world of enzyme inhibition and their effects on Biozyme-X, painting a comprehensive picture of the intricate interplay of molecules within her body.
A] Watch first this video on enzyme inhibition and also go through the related reading. In this video, we saw the use of an inhibitor resembling the structure of substrate phosphoenolpyruvate. Which inhibitor of Biozyme-X does this pyruvate kinase inhibitor resemble? Describe how this type of inhibition can work with Biozyme-X. Include in your discussion its effect on the various kinetic parameters.
B] In the video, we saw the use of inhibitors that can affect pyruvate kinase by binding away from the active site. Which inhibitor of Biozyme-X does this inhibitor of pyruvate kinase resemble? Describe how this type of inhibition can work with Biozyme-X. Include in your discussion its effect on the various kinetic parameters.
